Pharmaceuticals

Vyndaqel Market Developments And Opportunities Across 2026–2030

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Vyndaqel Market Be By 2030 Compared To Its 2026 Market Size?

The vyndaqel market has experienced rapid expansion in recent years. It is projected to increase from $1.9 billion in 2025 to $2.23 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.4%. Historically, this growth can be attributed to the approval of tafamidis, the limited availability of effective attr-cm treatments, advancements in cardiac imaging diagnostics, the development of rare disease programs, and an increase in cardiology referrals.

The vyndaqel market is projected for significant expansion over the upcoming years. By 2030, its value is anticipated to reach $4.19 billion, demonstrating a compound annual growth rate (CAGR) of 17.1%. This expansion during the projected timeframe is linked to factors such as an expanding elderly population, heightened understanding of amyloid cardiomyopathy, the proliferation of specialized cardiology centers, greater uptake of genetic testing, and enhanced reimbursement assistance. Key developments during this forecast period encompass the wider acceptance of transthyretin stabilizers, an uptick in the diagnosis of ATTR cardiomyopathy, the availability of more oral treatments for uncommon cardiac conditions, a stronger emphasis on drugs that modify cardiac diseases, and an extended application of long-term amyloidosis therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21321&type=smp

Which Primary Drivers Are Impacting The Vyndaqel Market Growth?

The increasing use of precision medicine is projected to stimulate the expansion of the Vyndaqel market. This approach customizes medical care for individual patients, considering their unique genetic makeup, environmental influences, and lifestyle choices, thereby enhancing the efficacy and results of treatments. Its uptake is rising because both patients and medical professionals increasingly favor customized treatments that provide precise care and more effective handling of chronic conditions. Vyndaqel complements precision medicine by delivering specific treatment for transthyretin amyloidosis (ATTR), ensuring that patients who stand to gain the most are the ones receiving it. An example of this trend is that, in February 2024, the US Food and Drug Administration (FDA) sanctioned 16 new personalized therapies for individuals with rare diseases in 2023, an increase from six in 2022, as reported by the US-based non-profit organization, the Personalized Medicine Coalition. Consequently, the expanding implementation of precision medicine is fueling the growth of the Vyndaqel market.

How Is Segmentation Applied In The Vyndaqel Market Segment Analysis?

The vyndaqel market covered in this report is segmented –

1) By Product Type: Vyndaqel (Tafamidis 20 mg), Vyndamax (Tafamidis 61 mg)

2) By Disease Type: Familial Amyloid Polyneuropathy (FAP), Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Vyndaqel (Tafamidis 20 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

2) By Vyndamax (Tafamidis 61 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

What Trends Are Influencing The Evolution Of The Vyndaqel Market?

Major companies operating within the vyndaqel market are concentrating on expanding their facilities to produce active pharmaceutical ingredients, such as transthyretin stabilizing therapeutic, with the goal of improving cardiovascular results and lessening hospital stays for patients with ATTR-CM. A transthyretin stabilizing therapeutic refers to a pharmacological agent engineered to bind to and stabilize transthyretin (TTR) tetramers, thereby preventing their dissociation into misfolded monomers that aggregate and form amyloid deposits. For instance, in November 2024, BridgeBio Pharma, a US-based biopharmaceutical company focused on genetic diseases, introduced Attruby (acoramidis), a near-complete (=90%) transthyretin (TTR) stabilizer developed to address key challenges in transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby (acoramidis) functions by binding and stabilizing TTR tetramers, preventing their separation into misfolded monomers that contribute to amyloid deposits in cardiac tissue. This therapy provides significant cardiovascular advantages, including a reduction in cardiovascular death and cardiovascular-related hospitalizations, while preserving TTR’s native physiological functions, making it an effective treatment for enhancing patient outcomes and disease management in ATTR-CM.

Who Are The Companies Participating In The Vyndaqel Market Environment?

Major companies operating in the vyndaqel market are Pfizer Inc.

Get The Full Vyndaqel Market Report:

https://www.thebusinessresearchcompany.com/report/vyndaqel-global-market-report

Where Is The Vyndaqel Market Primarily Concentrated By Region?

North America was the largest region in the vyndaqel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vyndaqel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Vyndaqel Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/vyndaqel-global-market-report

Browse Through More Reports Similar to the Global Vyndaqel Market 2026, By The Business Research Company

Virtual Assistant Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-assistant-global-market-report

Virtual Data Room Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-data-room-global-market-report

Vulvodynia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795